About Us

Established in 2013, NuBiyota is a pioneer in next-generation microbiome drug development. NuBiyota holds an exclusive license to the groundbreaking research developed at the University of Guelph, and led by co-founder, Dr. Emma Allen-Vercoe (PhD).

Dr. Allen-Vercoe is a prominent researcher in her field, with 25 years of experience in gut microbiology, the microbiota and its influence on health and disease. Dr. Allen-Vercoe has led multiple studies, published numerous academic papers , and has developed cutting edge innovations in her areas of expertise.

NuBiyota employs a world-class group of scientists and is led by a seasoned management team with extensive management and business development experience in the healthcare industry.

Together this team has developed a novel platform and a pipeline of microbiome therapeutic composition candidates for use in the treatment of medical indications, currently undergoing clinical testing.

NuBiyota has entered a strategic collaboration with the Takeda Pharmaceutical Company for the development of NuBiyota’s Microbial Ecosystem Therapeutic products for gastroenterology (GI) indications.

NuBiyota carries out its research activities in its state-of-the-art labs in Guelph, ON, Canada and has established a GMP manufacturing site in Pearl River, NY, USA.

Collaboration with Takeda to develop drugs for GI indications; MET-2 Canada Ph1 initiation for rCDI (recurrent Clostridioides Difficile Infection) indication.
Readout of multiple studies in Canada including rCDI, Metabolic, initial PD-1 safety and engraftment and Depression/anxiety.
Transition from rectally-delivered live microbial suspension to orally-delivered lyophilized capsule.
GMP manufacturing in Pearl River, NY
IND approved for phase 2 study in the US in metabolic disease.

NuBiyota’s Pillars of Success


  • Seasoned entrepreneurial founding team
  • World class scientific team



  • Strategic collaborations
  • Application of clinical data to identify disease correlations



  • Advanced CMC platform
  • Leverages proprietary IP



  • Partner with Takeda for GI indications
  • Open to partnering for additional indications



  • Pipeline of microbiome consortium candidates across multiple indications
  • Safety data from over 200 patients